• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Hero Background
    English
    Chinese
    French
    Japanese
    Korean
    German
    Spanish

    Psoriasis Treatment Market Share

    ID: MRFR/Pharma/2052-HCR
    200 Pages
    Rahul Gotadki
    October 2025

    Psoriasis Treatment Market Size, Growth Research Report By Treatment Type (Topical Treatments, Systemic Treatments, Phototherapy, Biologics), By Administration Route (Oral, Topical, Injectable, Intravenous), By Indication (Plaque Psoriasis, Guttate Psoriasis, Inverse Psoriasis, Pustular Psoriasis), By End User (Hospital, Dermatology Clinics, Homecare Settings) and By Regional (North America, Eu...

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Psoriasis Treatment Market Infographic
    Purchase Options

    Market Share

    Psoriasis Treatment Market Share Analysis

    Partnerships in the psoriasis treatment market purposely feature on biologic treatments, putting resources into research, improvement, alongside commercialization to ensure a significant piece of the pie, taking special care of the need for cutting edge medicines. Organizations perceive their psoriasis treatment contributions by making spearheading plans, including skin specialists, mix treatments, alongside upgraded conveyance frameworks, to do the trick explicit patient necessities and position themselves as leads. Organizations decisively develop their market section through essential unions, further developing circulation organizations, and joining new business sectors to grow piece of the pie and build up their presence in key regions. Organizations carry out a patient-driven procedure, putting resources into help programs as well as instructive missions to advance patient experience, foster brand devotion, and show a positive standing inside the psoriasis treatment market. Vital evaluating models offset adequacy with moderateness, affirming piece of the pie situating and mounting market entrance by examining market elements, contender rating, and patient socioeconomics. Organizations are intentionally situating themselves by growing particular solutions for paediatric psoriasis, getting an upper hand and securing a huge stake of this particular market. Computerized wellbeing arrangements are being bound together by organizations to revise patient commitment, remote checking, and treatment adherence, lining up with advancing medical services patterns. Putting resources into clinical Research and development is significant for piece of the pie situating in the psoriasis treatment market. This active methodology keeps firms at the vanguard of logical progressions and offers state of the art fixes. Key partnerships and authorizing arrangements are vital for piece of the pie situating, obtaining promising treatments, extending item portfolios, and sharing mastery, adding to showcase intensity and admittance to novel therapies. Biosimilars and generics are vital portion of the overall industry situating procedures for psoriasis treatments. Fruitful administrative exploring permits organizations to offer savvy choices, extending patient access, and catching portion of the overall industry. Adaptable showcasing and marking procedures are significant for keeping an upper hand, guaranteeing associations adjust to advertise patterns, patient inclinations, and contender moves. Keeping severe administrative rules and wellbeing conventions is urgent for acquiring piece of the pie in the psoriasis treatment industry, as it guarantees the constancy and dependability of treatments.

    Author
    Rahul Gotadki
    Assistant Manager

    He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

    Leave a Comment

    FAQs

    Which region holds the largest market share in the Global Psoriasis Treatment Market in 2024?

    In 2024, North America is expected to hold the largest market share valued at 2.85 USD Billion.

    What will the market value of Europe be in the Global Psoriasis Treatment Market by 2035?

    The market value in Europe is projected to be 3.5 USD Billion by 2035.

    What is the estimated market size for Biologics in the Global Psoriasis Treatment Market in 2024?

    Biologics are expected to be valued at 2.65 USD Billion in 2024.

    What opportunities exist in the Global Psoriasis Treatment Market for systemic treatments by 2035?

    Systemic treatments are projected to grow to 3.0 USD Billion by 2035, indicating significant market opportunities.

    Who are the key competitors in the Global Psoriasis Treatment Market?

    Major players in the market include Pfizer, Merck and Co, AbbVie, and Johnson and Johnson among others.

    What is the expected market value for Phototherapy in the Global Psoriasis Treatment Market in 2024?

    Phototherapy is anticipated to be valued at 1.0 USD Billion in 2024.

    What challenges does the Global Psoriasis Treatment Market face in growth?

    The market faces challenges from regulatory hurdles and the high cost of development for new treatments.

    Market Summary

    As per MRFR analysis, the Psoriasis Treatment Market Size was estimated at 7.45 USD Billion in 2024. The Psoriasis Treatment industry is projected to grow from 7.78 USD Billion in 2025 to 12.0 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 4.43 during the forecast period 2025 - 2035.

    Key Market Trends & Highlights

    The Psoriasis Treatment Market is experiencing a transformative shift towards innovative therapies and personalized care.

    • The rise of biologic therapies is reshaping treatment paradigms, particularly in North America, which remains the largest market. A personalized medicine approach is gaining traction, catering to the unique needs of patients across diverse demographics. Integration of digital health solutions is enhancing patient engagement and monitoring, especially in the rapidly growing Asia-Pacific region. The increasing prevalence of psoriasis and advancements in treatment modalities are driving market growth, particularly in the topical and biologic segments.

    Market Size & Forecast

    2024 Market Size 7.45 (USD Billion)
    2035 Market Size 12.0 (USD Billion)
    CAGR (2025 - 2035) 4.43%
    Largest Regional Market Share in 2024 North America

    Major Players

    <p>AbbVie (US), Amgen (US), Johnson &amp; Johnson (US), Novartis (CH), Bristol-Myers Squibb (US), GSK (GB), Eli Lilly (US), Sanofi (FR), UCB (BE)</p>

    Market Trends

    The Psoriasis Treatment Market is currently experiencing a dynamic evolution, driven by a combination of innovative therapies and a growing understanding of the disease's underlying mechanisms. Recent advancements in biologic treatments, which target specific pathways involved in the inflammatory process, appear to be reshaping the therapeutic landscape. Additionally, the increasing prevalence of psoriasis globally suggests a rising demand for effective treatment options. This trend is further supported by heightened awareness and education surrounding the condition, which encourages patients to seek medical advice and explore available therapies. Moreover, the market is witnessing a shift towards personalized medicine, where treatments are tailored to individual patient profiles. This approach not only enhances treatment efficacy but also minimizes potential side effects, thereby improving patient adherence. The integration of digital health technologies, such as telemedicine and mobile health applications, is also gaining traction, facilitating better patient management and follow-up care. As the Psoriasis Treatment Market continues to evolve, stakeholders must remain vigilant to emerging trends and adapt strategies accordingly to meet the diverse needs of patients and healthcare providers alike.

    Rise of Biologic Therapies

    The Psoriasis Treatment Market is increasingly characterized by the emergence of biologic therapies. These advanced treatments target specific components of the immune system, offering a more effective approach to managing psoriasis symptoms. As research progresses, the development of new biologics is likely to expand treatment options, potentially leading to improved patient outcomes.

    Personalized Medicine Approach

    There is a noticeable shift towards personalized medicine within the Psoriasis Treatment Market. Tailoring treatments to individual patient characteristics may enhance therapeutic effectiveness and reduce adverse effects. This trend suggests a growing recognition of the need for customized care in managing chronic conditions like psoriasis.

    Integration of Digital Health Solutions

    The incorporation of digital health solutions is transforming the Psoriasis Treatment Market. Telemedicine and mobile applications are facilitating better patient engagement and monitoring. This trend indicates a move towards more accessible and efficient healthcare delivery, which could significantly improve treatment adherence and patient satisfaction.

    <p>The increasing prevalence of psoriasis, coupled with advancements in biologic therapies, suggests a transformative shift in treatment paradigms that may enhance patient outcomes and quality of life.</p>

    National Institutes of Health

    Psoriasis Treatment Market Market Drivers

    Growing Awareness and Education

    The increasing awareness and education surrounding psoriasis are crucial drivers for the Psoriasis Treatment Market. Campaigns aimed at educating the public about the condition and its treatment options have led to a rise in diagnosis rates. Patients are now more informed about their treatment choices, which encourages them to seek medical advice. This heightened awareness is particularly evident in regions where healthcare initiatives focus on chronic diseases. As more individuals understand the implications of psoriasis, the demand for effective treatments is expected to rise, thereby propelling the Psoriasis Treatment Market forward.

    Increasing Prevalence of Psoriasis

    The rising incidence of psoriasis is a pivotal driver in the Psoriasis Treatment Market. Recent estimates indicate that approximately 2-3% of the population is affected by this chronic skin condition, leading to a growing demand for effective treatment options. As awareness of psoriasis increases, more individuals seek medical intervention, thereby expanding the market. The prevalence of psoriasis is particularly notable in developed regions, where healthcare access is more readily available. This trend suggests that the Psoriasis Treatment Market will continue to grow as healthcare providers develop new therapies to meet the needs of an expanding patient population.

    Advancements in Treatment Modalities

    Innovations in treatment modalities are significantly influencing the Psoriasis Treatment Market. The introduction of biologic therapies, which target specific pathways in the immune system, has transformed the treatment landscape. These therapies have shown efficacy in moderate to severe cases, leading to increased adoption among healthcare professionals. Furthermore, the market is witnessing a surge in topical treatments and systemic therapies, which cater to varying degrees of psoriasis severity. The continuous research and development efforts in this area indicate a promising future for the Psoriasis Treatment Market, as new and improved therapies are likely to emerge.

    Regulatory Support for New Therapies

    Regulatory support for the approval of new therapies is a vital driver in the Psoriasis Treatment Market. Regulatory agencies are increasingly expediting the review process for innovative treatments, particularly biologics and novel systemic therapies. This trend is encouraging pharmaceutical companies to invest in research and development, leading to a more diverse array of treatment options for patients. The favorable regulatory environment not only accelerates the availability of new therapies but also enhances competition within the market. As a result, the Psoriasis Treatment Market is likely to experience growth as new and effective treatments become accessible to patients.

    Rising Investment in Healthcare Infrastructure

    The expansion of healthcare infrastructure is a significant factor impacting the Psoriasis Treatment Market. Increased investment in healthcare facilities and services enhances access to dermatological care, which is essential for effective psoriasis management. Governments and private entities are focusing on improving healthcare systems, particularly in underserved areas. This investment is likely to facilitate better diagnosis and treatment options for psoriasis patients. As healthcare systems evolve, the Psoriasis Treatment Market is poised to benefit from improved patient access and a broader range of treatment modalities.

    Market Segment Insights

    By Type: Topical Treatments (Largest) vs. Biologics (Fastest-Growing)

    <p>In the Psoriasis Treatment Market, the Topical Treatments segment dominates the market share due to its widespread use and accessibility for patients. This segment includes various therapies such as corticosteroids, vitamin D analogs, and retinoids, which are effective for mild to moderate cases of psoriasis. On the other hand, Biologics, which are advanced medications targeting specific parts of the immune system, are gaining traction and hold a significant part of the market due to their effectiveness in severe cases, resulting in their rapid growth.</p>

    <p>Topical Treatments (Dominant) vs. Biologics (Emerging)</p>

    <p>Topical Treatments have established themselves as the cornerstone for managing psoriasis for many patients, especially those with mild to moderate conditions. These treatments are often preferred due to their ease of use, direct application, and lower risk of systemic side effects. In contrast, Biologics represent an emerging avenue in psoriasis therapy, offering targeted relief for moderate to severe cases through innovative methods that inhibit inflammatory pathways. Their increasing effectiveness and the medical community's growing familiarity with these drugs are driving rapid adoption. As a result, while Topical Treatments remain dominant, Biologics are set to capture a larger share of the market, owing to a favorable outlook and endorsement from dermatology guidelines.</p>

    By Administration Route: Topical (Largest) vs. Injectable (Fastest-Growing)

    <p>In the Psoriasis Treatment Market, the administration route segment displays significant diversity, with topical treatments holding the largest market share. These treatments are favored due to their direct application on affected areas, resulting in minimal systemic exposure. Injectables, while representing a smaller share currently, are emerging as a potent contender due to their efficacy and the increasing patient and physician acceptance. Oral and intravenous routes, though available, occupy more specialized niches within the market.</p>

    <p>Topical (Dominant) vs. Injectable (Emerging)</p>

    <p>Topical treatments for psoriasis, including creams, ointments, and gels, dominate the market due to their targeted nature and ease of use. They are widely preferred by patients and healthcare providers for milder cases and are often the first line of defense. Conversely, injectable treatments, such as <a href="https://www.marketresearchfuture.com/reports/biologics-market-1339">biologics</a>, are rapidly gaining traction as they offer significant relief for moderate to severe psoriasis. They harness advanced biotechnology and have shown impressive efficacy rates, making them an attractive option for treatment-resistant patients. This shift towards injectables represents a growing trend in the market, driven by continued advancements in technology and the increasing prevalence of psoriasis.</p>

    By Indication: Plaque Psoriasis (Largest) vs. Guttate Psoriasis (Fastest-Growing)

    <p>The psoriasis treatment market features a diverse range of indications, with Plaque Psoriasis accounting for the largest market share. This subtype is the most prevalent form of psoriasis and is characterized by raised, inflamed lesions covered with silvery scales. Guttate Psoriasis, while smaller in share compared to Plaque, has been noted for its rapid growth, primarily in younger populations and influenced by factors such as streptococcal infections. As the awareness and diagnosis of various psoriasis types improve, the market distribution reflects these changes in patient demographics and symptom presentations.</p>

    <p>Plaque Psoriasis (Dominant) vs. Guttate Psoriasis (Emerging)</p>

    <p>Plaque Psoriasis remains the dominant indication in the psoriasis treatment market, largely due to its high prevalence and the extensive range of effective therapies available. Patients with Plaque Psoriasis often experience chronic symptoms, leading to consistent demand for treatment options. In contrast, Guttate Psoriasis is emerging quickly, especially among adolescents and young adults, as it is often a result of infections or stress. While it may not be as well-known as Plaque, the increasing incidence rates and novel treatment approaches are propelling its market presence. Patients with Guttate are generally more receptive to new therapies, creating opportunities for innovative treatment options.</p>

    By End User: Hospital (Largest) vs. Dermatology Clinics (Fastest-Growing)

    <p>In the psoriasis treatment market, hospitals account for the largest share of the end user segment. This is primarily due to their capacity to offer comprehensive care, advanced treatment options, and the availability of specialist healthcare professionals. Dermatology clinics follow closely, yet they are witnessing an impressive surge in demand as more patients seek specialized care in a focused environment. Homecare settings are becoming increasingly relevant, particularly for those preferring convenience and personalized treatment regimens, although they hold a smaller share compared to hospitals and clinics.</p>

    <p>Dermatology Clinics (Dominant) vs. Homecare Settings (Emerging)</p>

    <p>Dermatology clinics serve as a dominant force in the psoriasis treatment market due to their targeted approach to skincare and treatment of specific conditions, which resonates well with patients seeking expert help. They not only provide customized treatment plans and access to cutting-edge therapies but also facilitate continuous monitoring of patients' progress, enhancing treatment efficacy. Conversely, homecare settings are emerging as a vital alternative, especially amid the growing trend of telemedicine and patient-centric care models. The convenience of managing psoriasis treatments at home appeals to many patients, especially those with mild to moderate conditions, thus fostering growth opportunities in this segment.</p>

    Get more detailed insights about Psoriasis Treatment Market Research Report - Forecast till 2035

    Regional Insights

    North America : Leading Market for Treatments

    North America is the largest market for psoriasis treatments, accounting for approximately 45% of the global market share. The region's growth is driven by increasing prevalence of psoriasis, advancements in treatment options, and supportive regulatory frameworks. The U.S. Food and Drug Administration (FDA) has accelerated the approval process for innovative therapies, enhancing market dynamics. The demand for biologics and targeted therapies is on the rise, further propelling market growth. The competitive landscape in North America is robust, with key players such as AbbVie, Amgen, and Johnson & Johnson leading the market. The presence of advanced healthcare infrastructure and high healthcare expenditure supports the adoption of new therapies. Additionally, ongoing clinical trials and research initiatives are expected to introduce novel treatment options, solidifying North America's position as a leader in the psoriasis treatment market.

    Europe : Emerging Market with Growth Potential

    Europe is the second-largest market for psoriasis treatments, holding approximately 30% of the global market share. The region is witnessing significant growth due to rising awareness about psoriasis, increasing healthcare investments, and favorable reimbursement policies. The European Medicines Agency (EMA) has been proactive in approving new therapies, which has stimulated market demand. The growing focus on personalized medicine is also a key driver of market expansion in Europe. Leading countries in Europe include Germany, France, and the UK, which are home to several prominent pharmaceutical companies. Key players such as Novartis, GSK, and Sanofi are actively involved in developing innovative treatments. The competitive landscape is characterized by a mix of established companies and emerging biotech firms, fostering a dynamic environment for psoriasis treatment advancements.

    Asia-Pacific : Rapidly Growing Treatment Sector

    The Asia-Pacific region is emerging as a significant player in the psoriasis treatment market, accounting for approximately 20% of the global market share. The growth is driven by increasing awareness of skin diseases, rising disposable incomes, and expanding healthcare access. Countries like China and India are witnessing a surge in demand for psoriasis treatments, supported by government initiatives aimed at improving healthcare infrastructure and access to medications. Regulatory bodies are also streamlining approval processes for new therapies, enhancing market dynamics. In the competitive landscape, key players such as Eli Lilly and Pfizer are making substantial investments in the region. The presence of local pharmaceutical companies is also increasing, contributing to a diverse market. The growing trend of telemedicine and digital health solutions is expected to further boost treatment accessibility and patient engagement in the Asia-Pacific region, driving future growth.

    Middle East and Africa : Emerging Market with Challenges

    The Middle East and Africa (MEA) region is gradually developing its psoriasis treatment market, holding approximately 5% of the global market share. The growth is hindered by challenges such as limited healthcare infrastructure, high treatment costs, and varying levels of awareness about psoriasis. However, increasing investments in healthcare and initiatives to improve access to treatments are expected to drive market growth in the coming years. Regulatory bodies are working to enhance the approval processes for new therapies, which could stimulate market dynamics. Leading countries in the MEA region include South Africa and the UAE, where there is a growing presence of international pharmaceutical companies. Key players are beginning to explore opportunities in this region, focusing on affordable treatment options. The competitive landscape is evolving, with local firms collaborating with global companies to enhance treatment availability and awareness, paving the way for future growth in the psoriasis treatment market.

    Key Players and Competitive Insights

    The Psoriasis Treatment Market is characterized by a dynamic competitive landscape, driven by a confluence of innovation, strategic partnerships, and a growing emphasis on personalized medicine. Major players such as AbbVie (US), Amgen (US), and Novartis (CH) are at the forefront, leveraging their extensive research capabilities and established market presence to enhance their product offerings. AbbVie (US) continues to focus on its flagship product, Humira, while also investing in the development of new therapies that target specific patient populations. Meanwhile, Amgen (US) is expanding its portfolio through strategic collaborations aimed at enhancing its biologics pipeline, which is crucial in addressing the diverse needs of psoriasis patients. Novartis (CH) is similarly positioned, emphasizing its commitment to innovation through the development of novel therapies that not only improve efficacy but also reduce treatment burden for patients.

    In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance efficiency and responsiveness to market demands. The competitive structure of the psoriasis treatment market appears moderately fragmented, with several key players exerting influence over various segments. This fragmentation allows for a diverse range of treatment options, catering to different patient demographics and preferences, while also fostering a competitive environment that encourages continuous innovation.

    In August 2025, AbbVie (US) announced a strategic partnership with a leading biotechnology firm to co-develop a new class of oral therapies for psoriasis. This collaboration is expected to accelerate the development timeline and enhance AbbVie’s competitive edge in the oral treatment segment, which is gaining traction among patients seeking alternatives to injectable therapies. The strategic importance of this partnership lies in its potential to broaden AbbVie’s market share and reinforce its position as a leader in psoriasis treatment.

    In September 2025, Amgen (US) launched a new digital health platform aimed at improving patient engagement and adherence to psoriasis treatments. This initiative reflects a growing trend towards digitalization in healthcare, where technology is leveraged to enhance patient outcomes. By integrating digital tools into its treatment protocols, Amgen (US) not only improves patient experience but also gathers valuable data that can inform future product development.

    In October 2025, Novartis (CH) unveiled a sustainability initiative focused on reducing the environmental impact of its manufacturing processes for psoriasis treatments. This move aligns with the increasing demand for sustainable practices within the pharmaceutical industry and positions Novartis as a forward-thinking player committed to corporate social responsibility. The strategic importance of this initiative is multifaceted, as it not only addresses regulatory pressures but also resonates with environmentally conscious consumers.

    As of October 2025, the competitive trends in the psoriasis treatment market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence in drug development. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in navigating complex market dynamics. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition towards a focus on innovation, technological advancements, and supply chain reliability, ultimately enhancing patient care and treatment outcomes.

    Key Companies in the Psoriasis Treatment Market market include

    Industry Developments

    In recent months, the Global Psoriasis Treatment Market has experienced significant developments, particularly with companies like AbbVie making strides in Research and Development for improved biologic therapies. In September 2023, Pfizer launched a new clinical trial aimed at exploring innovative treatments for moderate to severe psoriasis, showcasing ongoing commitment in this sector. Similarly, in August 2023, Merck announced advancements in their psoriasis portfolio, aimed at enhancing patient outcomes. 

    Major companies including Johnson and Johnson and Novartis continue to engage in improving treatment options, while GSK has been actively investing in research to tap into emerging treatment modalities. In terms of mergers and acquisitions, in July 2023, AstraZeneca completed the acquisition of a portfolio from a small biotech company focused on skin diseases, significantly enhancing their capabilities in the psoriasis market. 

    Reports indicate that there is growing momentum for biologic therapies, which has led to increased valuations for key players in the market. Over the past two to three years, the industry has witnessed a marked increase in interest and investment, particularly in targeting more effective treatment options for patients, as the demand for innovative solutions continues to rise globally.

    Future Outlook

    Psoriasis Treatment Market Future Outlook

    <p>The Psoriasis Treatment Market is projected to grow at a 4.43% CAGR from 2024 to 2035, driven by increasing prevalence, innovative therapies, and rising healthcare expenditure.</p>

    New opportunities lie in:

    • <p>Development of personalized biologic therapies targeting specific patient profiles.</p><p>Expansion of telehealth services for remote patient monitoring and consultations.</p><p>Investment in digital health platforms for treatment adherence and education.</p>

    <p>By 2035, the Psoriasis Treatment Market is expected to achieve substantial growth and innovation.</p>

    Market Segmentation

    Psoriasis Treatment Market Type Outlook

    • Topical Treatments
    • Systemic Treatments
    • Phototherapy
    • Biologics

    Psoriasis Treatment Market End User Outlook

    • Hospital
    • Dermatology Clinics
    • Homecare Settings

    Psoriasis Treatment Market Indication Outlook

    • Plaque Psoriasis
    • Guttate Psoriasis
    • Inverse Psoriasis
    • Pustular Psoriasis

    Psoriasis Treatment Market Administration Route Outlook

    • Oral
    • Topical
    • Injectable
    • Intravenous

    Report Scope

    MARKET SIZE 20247.45(USD Billion)
    MARKET SIZE 20257.78(USD Billion)
    MARKET SIZE 203512.0(USD Billion)
    COMPOUND ANNUAL GROWTH RATE (CAGR)4.43% (2024 - 2035)
    REPORT COVERAGERevenue Forecast, Competitive Landscape, Growth Factors, and Trends
    BASE YEAR2024
    Market Forecast Period2025 - 2035
    Historical Data2019 - 2024
    Market Forecast UnitsUSD Billion
    Key Companies ProfiledMarket analysis in progress
    Segments CoveredMarket segmentation analysis in progress
    Key Market OpportunitiesEmergence of biologics and personalized therapies enhances treatment options in the Psoriasis Treatment Market.
    Key Market DynamicsRising demand for biologics drives innovation and competition in the psoriasis treatment landscape.
    Countries CoveredNorth America, Europe, APAC, South America, MEA

    FAQs

    Which region holds the largest market share in the Global Psoriasis Treatment Market in 2024?

    In 2024, North America is expected to hold the largest market share valued at 2.85 USD Billion.

    What will the market value of Europe be in the Global Psoriasis Treatment Market by 2035?

    The market value in Europe is projected to be 3.5 USD Billion by 2035.

    What is the estimated market size for Biologics in the Global Psoriasis Treatment Market in 2024?

    Biologics are expected to be valued at 2.65 USD Billion in 2024.

    What opportunities exist in the Global Psoriasis Treatment Market for systemic treatments by 2035?

    Systemic treatments are projected to grow to 3.0 USD Billion by 2035, indicating significant market opportunities.

    Who are the key competitors in the Global Psoriasis Treatment Market?

    Major players in the market include Pfizer, Merck and Co, AbbVie, and Johnson and Johnson among others.

    What is the expected market value for Phototherapy in the Global Psoriasis Treatment Market in 2024?

    Phototherapy is anticipated to be valued at 1.0 USD Billion in 2024.

    What challenges does the Global Psoriasis Treatment Market face in growth?

    The market faces challenges from regulatory hurdles and the high cost of development for new treatments.

    1. SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
      1. | 1.1 EXECUTIVE SUMMARY
      2. | | 1.1.1 Market Overview
      3. | | 1.1.2 Key Findings
      4. | | 1.1.3 Market Segmentation
      5. | | 1.1.4 Competitive Landscape
      6. | | 1.1.5 Challenges and Opportunities
      7. | | 1.1.6 Future Outlook
    2. SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
      1. | 2.1 MARKET INTRODUCTION
      2. | | 2.1.1 Definition
      3. | | 2.1.2 Scope of the study
      4. | | | 2.1.2.1 Research Objective
      5. | | | 2.1.2.2 Assumption
      6. | | | 2.1.2.3 Limitations
      7. | 2.2 RESEARCH METHODOLOGY
      8. | | 2.2.1 Overview
      9. | | 2.2.2 Data Mining
      10. | | 2.2.3 Secondary Research
      11. | | 2.2.4 Primary Research
      12. | | | 2.2.4.1 Primary Interviews and Information Gathering Process
      13. | | | 2.2.4.2 Breakdown of Primary Respondents
      14. | | 2.2.5 Forecasting Model
      15. | | 2.2.6 Market Size Estimation
      16. | | | 2.2.6.1 Bottom-Up Approach
      17. | | | 2.2.6.2 Top-Down Approach
      18. | | 2.2.7 Data Triangulation
      19. | | 2.2.8 Validation
    3. SECTION III: QUALITATIVE ANALYSIS
      1. | 3.1 MARKET DYNAMICS
      2. | | 3.1.1 Overview
      3. | | 3.1.2 Drivers
      4. | | 3.1.3 Restraints
      5. | | 3.1.4 Opportunities
      6. | 3.2 MARKET FACTOR ANALYSIS
      7. | | 3.2.1 Value chain Analysis
      8. | | 3.2.2 Porter's Five Forces Analysis
      9. | | | 3.2.2.1 Bargaining Power of Suppliers
      10. | | | 3.2.2.2 Bargaining Power of Buyers
      11. | | | 3.2.2.3 Threat of New Entrants
      12. | | | 3.2.2.4 Threat of Substitutes
      13. | | | 3.2.2.5 Intensity of Rivalry
      14. | | 3.2.3 COVID-19 Impact Analysis
      15. | | | 3.2.3.1 Market Impact Analysis
      16. | | | 3.2.3.2 Regional Impact
      17. | | | 3.2.3.3 Opportunity and Threat Analysis
    4. SECTION IV: QUANTITATIVE ANALYSIS
      1. | 4.1 Healthcare, BY Type (USD Billion)
      2. | | 4.1.1 Topical Treatments
      3. | | 4.1.2 Systemic Treatments
      4. | | 4.1.3 Phototherapy
      5. | | 4.1.4 Biologics
      6. | 4.2 Healthcare, BY Administration Route (USD Billion)
      7. | | 4.2.1 Oral
      8. | | 4.2.2 Topical
      9. | | 4.2.3 Injectable
      10. | | 4.2.4 Intravenous
      11. | 4.3 Healthcare, BY Indication (USD Billion)
      12. | | 4.3.1 Plaque Psoriasis
      13. | | 4.3.2 Guttate Psoriasis
      14. | | 4.3.3 Inverse Psoriasis
      15. | | 4.3.4 Pustular Psoriasis
      16. | 4.4 Healthcare, BY End User (USD Billion)
      17. | | 4.4.1 Hospital
      18. | | 4.4.2 Dermatology Clinics
      19. | | 4.4.3 Homecare Settings
      20. | 4.5 Healthcare, BY Region (USD Billion)
      21. | | 4.5.1 North America
      22. | | | 4.5.1.1 US
      23. | | | 4.5.1.2 Canada
      24. | | 4.5.2 Europe
      25. | | | 4.5.2.1 Germany
      26. | | | 4.5.2.2 UK
      27. | | | 4.5.2.3 France
      28. | | | 4.5.2.4 Russia
      29. | | | 4.5.2.5 Italy
      30. | | | 4.5.2.6 Spain
      31. | | | 4.5.2.7 Rest of Europe
      32. | | 4.5.3 APAC
      33. | | | 4.5.3.1 China
      34. | | | 4.5.3.2 India
      35. | | | 4.5.3.3 Japan
      36. | | | 4.5.3.4 South Korea
      37. | | | 4.5.3.5 Malaysia
      38. | | | 4.5.3.6 Thailand
      39. | | | 4.5.3.7 Indonesia
      40. | | | 4.5.3.8 Rest of APAC
      41. | | 4.5.4 South America
      42. | | | 4.5.4.1 Brazil
      43. | | | 4.5.4.2 Mexico
      44. | | | 4.5.4.3 Argentina
      45. | | | 4.5.4.4 Rest of South America
      46. | | 4.5.5 MEA
      47. | | | 4.5.5.1 GCC Countries
      48. | | | 4.5.5.2 South Africa
      49. | | | 4.5.5.3 Rest of MEA
    5. SECTION V: COMPETITIVE ANALYSIS
      1. | 5.1 Competitive Landscape
      2. | | 5.1.1 Overview
      3. | | 5.1.2 Competitive Analysis
      4. | | 5.1.3 Market share Analysis
      5. | | 5.1.4 Major Growth Strategy in the Healthcare
      6. | | 5.1.5 Competitive Benchmarking
      7. | | 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
      8. | | 5.1.7 Key developments and growth strategies
      9. | | | 5.1.7.1 New Product Launch/Service Deployment
      10. | | | 5.1.7.2 Merger & Acquisitions
      11. | | | 5.1.7.3 Joint Ventures
      12. | | 5.1.8 Major Players Financial Matrix
      13. | | | 5.1.8.1 Sales and Operating Income
      14. | | | 5.1.8.2 Major Players R&D Expenditure. 2023
      15. | 5.2 Company Profiles
      16. | | 5.2.1 AbbVie (US)
      17. | | | 5.2.1.1 Financial Overview
      18. | | | 5.2.1.2 Products Offered
      19. | | | 5.2.1.3 Key Developments
      20. | | | 5.2.1.4 SWOT Analysis
      21. | | | 5.2.1.5 Key Strategies
      22. | | 5.2.2 Amgen (US)
      23. | | | 5.2.2.1 Financial Overview
      24. | | | 5.2.2.2 Products Offered
      25. | | | 5.2.2.3 Key Developments
      26. | | | 5.2.2.4 SWOT Analysis
      27. | | | 5.2.2.5 Key Strategies
      28. | | 5.2.3 Johnson & Johnson (US)
      29. | | | 5.2.3.1 Financial Overview
      30. | | | 5.2.3.2 Products Offered
      31. | | | 5.2.3.3 Key Developments
      32. | | | 5.2.3.4 SWOT Analysis
      33. | | | 5.2.3.5 Key Strategies
      34. | | 5.2.4 Novartis (CH)
      35. | | | 5.2.4.1 Financial Overview
      36. | | | 5.2.4.2 Products Offered
      37. | | | 5.2.4.3 Key Developments
      38. | | | 5.2.4.4 SWOT Analysis
      39. | | | 5.2.4.5 Key Strategies
      40. | | 5.2.5 Bristol-Myers Squibb (US)
      41. | | | 5.2.5.1 Financial Overview
      42. | | | 5.2.5.2 Products Offered
      43. | | | 5.2.5.3 Key Developments
      44. | | | 5.2.5.4 SWOT Analysis
      45. | | | 5.2.5.5 Key Strategies
      46. | | 5.2.6 GSK (GB)
      47. | | | 5.2.6.1 Financial Overview
      48. | | | 5.2.6.2 Products Offered
      49. | | | 5.2.6.3 Key Developments
      50. | | | 5.2.6.4 SWOT Analysis
      51. | | | 5.2.6.5 Key Strategies
      52. | | 5.2.7 Eli Lilly (US)
      53. | | | 5.2.7.1 Financial Overview
      54. | | | 5.2.7.2 Products Offered
      55. | | | 5.2.7.3 Key Developments
      56. | | | 5.2.7.4 SWOT Analysis
      57. | | | 5.2.7.5 Key Strategies
      58. | | 5.2.8 Sanofi (FR)
      59. | | | 5.2.8.1 Financial Overview
      60. | | | 5.2.8.2 Products Offered
      61. | | | 5.2.8.3 Key Developments
      62. | | | 5.2.8.4 SWOT Analysis
      63. | | | 5.2.8.5 Key Strategies
      64. | | 5.2.9 Pfizer (US)
      65. | | | 5.2.9.1 Financial Overview
      66. | | | 5.2.9.2 Products Offered
      67. | | | 5.2.9.3 Key Developments
      68. | | | 5.2.9.4 SWOT Analysis
      69. | | | 5.2.9.5 Key Strategies
      70. | 5.3 Appendix
      71. | | 5.3.1 References
      72. | | 5.3.2 Related Reports
    6. LIST OF FIGURES
      1. | 6.1 MARKET SYNOPSIS
      2. | 6.2 NORTH AMERICA MARKET ANALYSIS
      3. | 6.3 US MARKET ANALYSIS BY TYPE
      4. | 6.4 US MARKET ANALYSIS BY ADMINISTRATION ROUTE
      5. | 6.5 US MARKET ANALYSIS BY INDICATION
      6. | 6.6 US MARKET ANALYSIS BY END USER
      7. | 6.7 CANADA MARKET ANALYSIS BY TYPE
      8. | 6.8 CANADA MARKET ANALYSIS BY ADMINISTRATION ROUTE
      9. | 6.9 CANADA MARKET ANALYSIS BY INDICATION
      10. | 6.10 CANADA MARKET ANALYSIS BY END USER
      11. | 6.11 EUROPE MARKET ANALYSIS
      12. | 6.12 GERMANY MARKET ANALYSIS BY TYPE
      13. | 6.13 GERMANY MARKET ANALYSIS BY ADMINISTRATION ROUTE
      14. | 6.14 GERMANY MARKET ANALYSIS BY INDICATION
      15. | 6.15 GERMANY MARKET ANALYSIS BY END USER
      16. | 6.16 UK MARKET ANALYSIS BY TYPE
      17. | 6.17 UK MARKET ANALYSIS BY ADMINISTRATION ROUTE
      18. | 6.18 UK MARKET ANALYSIS BY INDICATION
      19. | 6.19 UK MARKET ANALYSIS BY END USER
      20. | 6.20 FRANCE MARKET ANALYSIS BY TYPE
      21. | 6.21 FRANCE MARKET ANALYSIS BY ADMINISTRATION ROUTE
      22. | 6.22 FRANCE MARKET ANALYSIS BY INDICATION
      23. | 6.23 FRANCE MARKET ANALYSIS BY END USER
      24. | 6.24 RUSSIA MARKET ANALYSIS BY TYPE
      25. | 6.25 RUSSIA MARKET ANALYSIS BY ADMINISTRATION ROUTE
      26. | 6.26 RUSSIA MARKET ANALYSIS BY INDICATION
      27. | 6.27 RUSSIA MARKET ANALYSIS BY END USER
      28. | 6.28 ITALY MARKET ANALYSIS BY TYPE
      29. | 6.29 ITALY MARKET ANALYSIS BY ADMINISTRATION ROUTE
      30. | 6.30 ITALY MARKET ANALYSIS BY INDICATION
      31. | 6.31 ITALY MARKET ANALYSIS BY END USER
      32. | 6.32 SPAIN MARKET ANALYSIS BY TYPE
      33. | 6.33 SPAIN MARKET ANALYSIS BY ADMINISTRATION ROUTE
      34. | 6.34 SPAIN MARKET ANALYSIS BY INDICATION
      35. | 6.35 SPAIN MARKET ANALYSIS BY END USER
      36. | 6.36 REST OF EUROPE MARKET ANALYSIS BY TYPE
      37. | 6.37 REST OF EUROPE MARKET ANALYSIS BY ADMINISTRATION ROUTE
      38. | 6.38 REST OF EUROPE MARKET ANALYSIS BY INDICATION
      39. | 6.39 REST OF EUROPE MARKET ANALYSIS BY END USER
      40. | 6.40 APAC MARKET ANALYSIS
      41. | 6.41 CHINA MARKET ANALYSIS BY TYPE
      42. | 6.42 CHINA MARKET ANALYSIS BY ADMINISTRATION ROUTE
      43. | 6.43 CHINA MARKET ANALYSIS BY INDICATION
      44. | 6.44 CHINA MARKET ANALYSIS BY END USER
      45. | 6.45 INDIA MARKET ANALYSIS BY TYPE
      46. | 6.46 INDIA MARKET ANALYSIS BY ADMINISTRATION ROUTE
      47. | 6.47 INDIA MARKET ANALYSIS BY INDICATION
      48. | 6.48 INDIA MARKET ANALYSIS BY END USER
      49. | 6.49 JAPAN MARKET ANALYSIS BY TYPE
      50. | 6.50 JAPAN MARKET ANALYSIS BY ADMINISTRATION ROUTE
      51. | 6.51 JAPAN MARKET ANALYSIS BY INDICATION
      52. | 6.52 JAPAN MARKET ANALYSIS BY END USER
      53. | 6.53 SOUTH KOREA MARKET ANALYSIS BY TYPE
      54. | 6.54 SOUTH KOREA MARKET ANALYSIS BY ADMINISTRATION ROUTE
      55. | 6.55 SOUTH KOREA MARKET ANALYSIS BY INDICATION
      56. | 6.56 SOUTH KOREA MARKET ANALYSIS BY END USER
      57. | 6.57 MALAYSIA MARKET ANALYSIS BY TYPE
      58. | 6.58 MALAYSIA MARKET ANALYSIS BY ADMINISTRATION ROUTE
      59. | 6.59 MALAYSIA MARKET ANALYSIS BY INDICATION
      60. | 6.60 MALAYSIA MARKET ANALYSIS BY END USER
      61. | 6.61 THAILAND MARKET ANALYSIS BY TYPE
      62. | 6.62 THAILAND MARKET ANALYSIS BY ADMINISTRATION ROUTE
      63. | 6.63 THAILAND MARKET ANALYSIS BY INDICATION
      64. | 6.64 THAILAND MARKET ANALYSIS BY END USER
      65. | 6.65 INDONESIA MARKET ANALYSIS BY TYPE
      66. | 6.66 INDONESIA MARKET ANALYSIS BY ADMINISTRATION ROUTE
      67. | 6.67 INDONESIA MARKET ANALYSIS BY INDICATION
      68. | 6.68 INDONESIA MARKET ANALYSIS BY END USER
      69. | 6.69 REST OF APAC MARKET ANALYSIS BY TYPE
      70. | 6.70 REST OF APAC MARKET ANALYSIS BY ADMINISTRATION ROUTE
      71. | 6.71 REST OF APAC MARKET ANALYSIS BY INDICATION
      72. | 6.72 REST OF APAC MARKET ANALYSIS BY END USER
      73. | 6.73 SOUTH AMERICA MARKET ANALYSIS
      74. | 6.74 BRAZIL MARKET ANALYSIS BY TYPE
      75. | 6.75 BRAZIL MARKET ANALYSIS BY ADMINISTRATION ROUTE
      76. | 6.76 BRAZIL MARKET ANALYSIS BY INDICATION
      77. | 6.77 BRAZIL MARKET ANALYSIS BY END USER
      78. | 6.78 MEXICO MARKET ANALYSIS BY TYPE
      79. | 6.79 MEXICO MARKET ANALYSIS BY ADMINISTRATION ROUTE
      80. | 6.80 MEXICO MARKET ANALYSIS BY INDICATION
      81. | 6.81 MEXICO MARKET ANALYSIS BY END USER
      82. | 6.82 ARGENTINA MARKET ANALYSIS BY TYPE
      83. | 6.83 ARGENTINA MARKET ANALYSIS BY ADMINISTRATION ROUTE
      84. | 6.84 ARGENTINA MARKET ANALYSIS BY INDICATION
      85. | 6.85 ARGENTINA MARKET ANALYSIS BY END USER
      86. | 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE
      87. | 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY ADMINISTRATION ROUTE
      88. | 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY INDICATION
      89. | 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY END USER
      90. | 6.90 MEA MARKET ANALYSIS
      91. | 6.91 GCC COUNTRIES MARKET ANALYSIS BY TYPE
      92. | 6.92 GCC COUNTRIES MARKET ANALYSIS BY ADMINISTRATION ROUTE
      93. | 6.93 GCC COUNTRIES MARKET ANALYSIS BY INDICATION
      94. | 6.94 GCC COUNTRIES MARKET ANALYSIS BY END USER
      95. | 6.95 SOUTH AFRICA MARKET ANALYSIS BY TYPE
      96. | 6.96 SOUTH AFRICA MARKET ANALYSIS BY ADMINISTRATION ROUTE
      97. | 6.97 SOUTH AFRICA MARKET ANALYSIS BY INDICATION
      98. | 6.98 SOUTH AFRICA MARKET ANALYSIS BY END USER
      99. | 6.99 REST OF MEA MARKET ANALYSIS BY TYPE
      100. | 6.100 REST OF MEA MARKET ANALYSIS BY ADMINISTRATION ROUTE
      101. | 6.101 REST OF MEA MARKET ANALYSIS BY INDICATION
      102. | 6.102 REST OF MEA MARKET ANALYSIS BY END USER
      103. | 6.103 KEY BUYING CRITERIA OF HEALTHCARE
      104. | 6.104 RESEARCH PROCESS OF MRFR
      105. | 6.105 DRO ANALYSIS OF HEALTHCARE
      106. | 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
      107. | 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
      108. | 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
      109. | 6.109 HEALTHCARE, BY TYPE, 2024 (% SHARE)
      110. | 6.110 HEALTHCARE, BY TYPE, 2024 TO 2035 (USD Billion)
      111. | 6.111 HEALTHCARE, BY ADMINISTRATION ROUTE, 2024 (% SHARE)
      112. | 6.112 HEALTHCARE, BY ADMINISTRATION ROUTE, 2024 TO 2035 (USD Billion)
      113. | 6.113 HEALTHCARE, BY INDICATION, 2024 (% SHARE)
      114. | 6.114 HEALTHCARE, BY INDICATION, 2024 TO 2035 (USD Billion)
      115. | 6.115 HEALTHCARE, BY END USER, 2024 (% SHARE)
      116. | 6.116 HEALTHCARE, BY END USER, 2024 TO 2035 (USD Billion)
      117. | 6.117 BENCHMARKING OF MAJOR COMPETITORS
    7. LIST OF TABLES
      1. | 7.1 LIST OF ASSUMPTIONS
      2. | | 7.1.1
      3. | 7.2 North America MARKET SIZE ESTIMATES; FORECAST
      4. | | 7.2.1 BY TYPE, 2025-2035 (USD Billion)
      5. | | 7.2.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
      6. | | 7.2.3 BY INDICATION, 2025-2035 (USD Billion)
      7. | | 7.2.4 BY END USER, 2025-2035 (USD Billion)
      8. | 7.3 US MARKET SIZE ESTIMATES; FORECAST
      9. | | 7.3.1 BY TYPE, 2025-2035 (USD Billion)
      10. | | 7.3.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
      11. | | 7.3.3 BY INDICATION, 2025-2035 (USD Billion)
      12. | | 7.3.4 BY END USER, 2025-2035 (USD Billion)
      13. | 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
      14. | | 7.4.1 BY TYPE, 2025-2035 (USD Billion)
      15. | | 7.4.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
      16. | | 7.4.3 BY INDICATION, 2025-2035 (USD Billion)
      17. | | 7.4.4 BY END USER, 2025-2035 (USD Billion)
      18. | 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
      19. | | 7.5.1 BY TYPE, 2025-2035 (USD Billion)
      20. | | 7.5.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
      21. | | 7.5.3 BY INDICATION, 2025-2035 (USD Billion)
      22. | | 7.5.4 BY END USER, 2025-2035 (USD Billion)
      23. | 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
      24. | | 7.6.1 BY TYPE, 2025-2035 (USD Billion)
      25. | | 7.6.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
      26. | | 7.6.3 BY INDICATION, 2025-2035 (USD Billion)
      27. | | 7.6.4 BY END USER, 2025-2035 (USD Billion)
      28. | 7.7 UK MARKET SIZE ESTIMATES; FORECAST
      29. | | 7.7.1 BY TYPE, 2025-2035 (USD Billion)
      30. | | 7.7.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
      31. | | 7.7.3 BY INDICATION, 2025-2035 (USD Billion)
      32. | | 7.7.4 BY END USER, 2025-2035 (USD Billion)
      33. | 7.8 France MARKET SIZE ESTIMATES; FORECAST
      34. | | 7.8.1 BY TYPE, 2025-2035 (USD Billion)
      35. | | 7.8.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
      36. | | 7.8.3 BY INDICATION, 2025-2035 (USD Billion)
      37. | | 7.8.4 BY END USER, 2025-2035 (USD Billion)
      38. | 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
      39. | | 7.9.1 BY TYPE, 2025-2035 (USD Billion)
      40. | | 7.9.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
      41. | | 7.9.3 BY INDICATION, 2025-2035 (USD Billion)
      42. | | 7.9.4 BY END USER, 2025-2035 (USD Billion)
      43. | 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
      44. | | 7.10.1 BY TYPE, 2025-2035 (USD Billion)
      45. | | 7.10.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
      46. | | 7.10.3 BY INDICATION, 2025-2035 (USD Billion)
      47. | | 7.10.4 BY END USER, 2025-2035 (USD Billion)
      48. | 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
      49. | | 7.11.1 BY TYPE, 2025-2035 (USD Billion)
      50. | | 7.11.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
      51. | | 7.11.3 BY INDICATION, 2025-2035 (USD Billion)
      52. | | 7.11.4 BY END USER, 2025-2035 (USD Billion)
      53. | 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
      54. | | 7.12.1 BY TYPE, 2025-2035 (USD Billion)
      55. | | 7.12.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
      56. | | 7.12.3 BY INDICATION, 2025-2035 (USD Billion)
      57. | | 7.12.4 BY END USER, 2025-2035 (USD Billion)
      58. | 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
      59. | | 7.13.1 BY TYPE, 2025-2035 (USD Billion)
      60. | | 7.13.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
      61. | | 7.13.3 BY INDICATION, 2025-2035 (USD Billion)
      62. | | 7.13.4 BY END USER, 2025-2035 (USD Billion)
      63. | 7.14 China MARKET SIZE ESTIMATES; FORECAST
      64. | | 7.14.1 BY TYPE, 2025-2035 (USD Billion)
      65. | | 7.14.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
      66. | | 7.14.3 BY INDICATION, 2025-2035 (USD Billion)
      67. | | 7.14.4 BY END USER, 2025-2035 (USD Billion)
      68. | 7.15 India MARKET SIZE ESTIMATES; FORECAST
      69. | | 7.15.1 BY TYPE, 2025-2035 (USD Billion)
      70. | | 7.15.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
      71. | | 7.15.3 BY INDICATION, 2025-2035 (USD Billion)
      72. | | 7.15.4 BY END USER, 2025-2035 (USD Billion)
      73. | 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
      74. | | 7.16.1 BY TYPE, 2025-2035 (USD Billion)
      75. | | 7.16.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
      76. | | 7.16.3 BY INDICATION, 2025-2035 (USD Billion)
      77. | | 7.16.4 BY END USER, 2025-2035 (USD Billion)
      78. | 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
      79. | | 7.17.1 BY TYPE, 2025-2035 (USD Billion)
      80. | | 7.17.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
      81. | | 7.17.3 BY INDICATION, 2025-2035 (USD Billion)
      82. | | 7.17.4 BY END USER, 2025-2035 (USD Billion)
      83. | 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
      84. | | 7.18.1 BY TYPE, 2025-2035 (USD Billion)
      85. | | 7.18.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
      86. | | 7.18.3 BY INDICATION, 2025-2035 (USD Billion)
      87. | | 7.18.4 BY END USER, 2025-2035 (USD Billion)
      88. | 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
      89. | | 7.19.1 BY TYPE, 2025-2035 (USD Billion)
      90. | | 7.19.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
      91. | | 7.19.3 BY INDICATION, 2025-2035 (USD Billion)
      92. | | 7.19.4 BY END USER, 2025-2035 (USD Billion)
      93. | 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
      94. | | 7.20.1 BY TYPE, 2025-2035 (USD Billion)
      95. | | 7.20.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
      96. | | 7.20.3 BY INDICATION, 2025-2035 (USD Billion)
      97. | | 7.20.4 BY END USER, 2025-2035 (USD Billion)
      98. | 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
      99. | | 7.21.1 BY TYPE, 2025-2035 (USD Billion)
      100. | | 7.21.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
      101. | | 7.21.3 BY INDICATION, 2025-2035 (USD Billion)
      102. | | 7.21.4 BY END USER, 2025-2035 (USD Billion)
      103. | 7.22 South America MARKET SIZE ESTIMATES; FORECAST
      104. | | 7.22.1 BY TYPE, 2025-2035 (USD Billion)
      105. | | 7.22.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
      106. | | 7.22.3 BY INDICATION, 2025-2035 (USD Billion)
      107. | | 7.22.4 BY END USER, 2025-2035 (USD Billion)
      108. | 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
      109. | | 7.23.1 BY TYPE, 2025-2035 (USD Billion)
      110. | | 7.23.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
      111. | | 7.23.3 BY INDICATION, 2025-2035 (USD Billion)
      112. | | 7.23.4 BY END USER, 2025-2035 (USD Billion)
      113. | 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
      114. | | 7.24.1 BY TYPE, 2025-2035 (USD Billion)
      115. | | 7.24.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
      116. | | 7.24.3 BY INDICATION, 2025-2035 (USD Billion)
      117. | | 7.24.4 BY END USER, 2025-2035 (USD Billion)
      118. | 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
      119. | | 7.25.1 BY TYPE, 2025-2035 (USD Billion)
      120. | | 7.25.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
      121. | | 7.25.3 BY INDICATION, 2025-2035 (USD Billion)
      122. | | 7.25.4 BY END USER, 2025-2035 (USD Billion)
      123. | 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
      124. | | 7.26.1 BY TYPE, 2025-2035 (USD Billion)
      125. | | 7.26.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
      126. | | 7.26.3 BY INDICATION, 2025-2035 (USD Billion)
      127. | | 7.26.4 BY END USER, 2025-2035 (USD Billion)
      128. | 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
      129. | | 7.27.1 BY TYPE, 2025-2035 (USD Billion)
      130. | | 7.27.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
      131. | | 7.27.3 BY INDICATION, 2025-2035 (USD Billion)
      132. | | 7.27.4 BY END USER, 2025-2035 (USD Billion)
      133. | 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
      134. | | 7.28.1 BY TYPE, 2025-2035 (USD Billion)
      135. | | 7.28.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
      136. | | 7.28.3 BY INDICATION, 2025-2035 (USD Billion)
      137. | | 7.28.4 BY END USER, 2025-2035 (USD Billion)
      138. | 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
      139. | | 7.29.1 BY TYPE, 2025-2035 (USD Billion)
      140. | | 7.29.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
      141. | | 7.29.3 BY INDICATION, 2025-2035 (USD Billion)
      142. | | 7.29.4 BY END USER, 2025-2035 (USD Billion)
      143. | 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
      144. | | 7.30.1 BY TYPE, 2025-2035 (USD Billion)
      145. | | 7.30.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
      146. | | 7.30.3 BY INDICATION, 2025-2035 (USD Billion)
      147. | | 7.30.4 BY END USER, 2025-2035 (USD Billion)
      148. | 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
      149. | | 7.31.1
      150. | 7.32 ACQUISITION/PARTNERSHIP
      151. | | 7.32.1

    Psoriasis Treatment Market Segmentation

    Psoriasis Treatment Market By Treatment Type (USD Billion, 2019-2035)

    Topical Treatments

    Systemic Treatments

    Phototherapy

    Biologics

    Psoriasis Treatment Market By Administration Route (USD Billion, 2019-2035)

    Oral

    Topical

    Injectable

    Intravenous

    Psoriasis Treatment Market By Indication (USD Billion, 2019-2035)

    Plaque Psoriasis

    Guttate Psoriasis

    Inverse Psoriasis

    Pustular Psoriasis

    Psoriasis Treatment Market By End User (USD Billion, 2019-2035)

    Hospital

    Dermatology Clinics

    Homecare Settings

    Psoriasis Treatment Market By Regional (USD Billion, 2019-2035)

    North America

    Europe

    South America

    Asia Pacific

    Middle East and Africa

    Psoriasis Treatment Market Regional Outlook (USD Billion, 2019-2035)

    North America Outlook (USD Billion, 2019-2035)

    North America Psoriasis Treatment Market by Treatment Type

    Topical Treatments

    Systemic Treatments

    Phototherapy

    Biologics

    North America Psoriasis Treatment Market by Administration Route Type

    Oral

    Topical

    Injectable

    Intravenous

    North America Psoriasis Treatment Market by Indication Type

    Plaque Psoriasis

    Guttate Psoriasis

    Inverse Psoriasis

    Pustular Psoriasis

    North America Psoriasis Treatment Market by End User Type

    Hospital

    Dermatology Clinics

    Homecare Settings

    North America Psoriasis Treatment Market by Regional Type

    US

    Canada

    US Outlook (USD Billion, 2019-2035)

    US Psoriasis Treatment Market by Treatment Type

    Topical Treatments

    Systemic Treatments

    Phototherapy

    Biologics

    US Psoriasis Treatment Market by Administration Route Type

    Oral

    Topical

    Injectable

    Intravenous

    US Psoriasis Treatment Market by Indication Type

    Plaque Psoriasis

    Guttate Psoriasis

    Inverse Psoriasis

    Pustular Psoriasis

    US Psoriasis Treatment Market by End User Type

    Hospital

    Dermatology Clinics

    Homecare Settings

    CANADA Outlook (USD Billion, 2019-2035)

    CANADA Psoriasis Treatment Market by Treatment Type

    Topical Treatments

    Systemic Treatments

    Phototherapy

    Biologics

    CANADA Psoriasis Treatment Market by Administration Route Type

    Oral

    Topical

    Injectable

    Intravenous

    CANADA Psoriasis Treatment Market by Indication Type

    Plaque Psoriasis

    Guttate Psoriasis

    Inverse Psoriasis

    Pustular Psoriasis

    CANADA Psoriasis Treatment Market by End User Type

    Hospital

    Dermatology Clinics

    Homecare Settings

    Europe Outlook (USD Billion, 2019-2035)

    Europe Psoriasis Treatment Market by Treatment Type

    Topical Treatments

    Systemic Treatments

    Phototherapy

    Biologics

    Europe Psoriasis Treatment Market by Administration Route Type

    Oral

    Topical

    Injectable

    Intravenous

    Europe Psoriasis Treatment Market by Indication Type

    Plaque Psoriasis

    Guttate Psoriasis

    Inverse Psoriasis

    Pustular Psoriasis

    Europe Psoriasis Treatment Market by End User Type

    Hospital

    Dermatology Clinics

    Homecare Settings

    Europe Psoriasis Treatment Market by Regional Type

    Germany

    UK

    France

    Russia

    Italy

    Spain

    Rest of Europe

    GERMANY Outlook (USD Billion, 2019-2035)

    GERMANY Psoriasis Treatment Market by Treatment Type

    Topical Treatments

    Systemic Treatments

    Phototherapy

    Biologics

    GERMANY Psoriasis Treatment Market by Administration Route Type

    Oral

    Topical

    Injectable

    Intravenous

    GERMANY Psoriasis Treatment Market by Indication Type

    Plaque Psoriasis

    Guttate Psoriasis

    Inverse Psoriasis

    Pustular Psoriasis

    GERMANY Psoriasis Treatment Market by End User Type

    Hospital

    Dermatology Clinics

    Homecare Settings

    UK Outlook (USD Billion, 2019-2035)

    UK Psoriasis Treatment Market by Treatment Type

    Topical Treatments

    Systemic Treatments

    Phototherapy

    Biologics

    UK Psoriasis Treatment Market by Administration Route Type

    Oral

    Topical

    Injectable

    Intravenous

    UK Psoriasis Treatment Market by Indication Type

    Plaque Psoriasis

    Guttate Psoriasis

    Inverse Psoriasis

    Pustular Psoriasis

    UK Psoriasis Treatment Market by End User Type

    Hospital

    Dermatology Clinics

    Homecare Settings

    FRANCE Outlook (USD Billion, 2019-2035)

    FRANCE Psoriasis Treatment Market by Treatment Type

    Topical Treatments

    Systemic Treatments

    Phototherapy

    Biologics

    FRANCE Psoriasis Treatment Market by Administration Route Type

    Oral

    Topical

    Injectable

    Intravenous

    FRANCE Psoriasis Treatment Market by Indication Type

    Plaque Psoriasis

    Guttate Psoriasis

    Inverse Psoriasis

    Pustular Psoriasis

    FRANCE Psoriasis Treatment Market by End User Type

    Hospital

    Dermatology Clinics

    Homecare Settings

    RUSSIA Outlook (USD Billion, 2019-2035)

    RUSSIA Psoriasis Treatment Market by Treatment Type

    Topical Treatments

    Systemic Treatments

    Phototherapy

    Biologics

    RUSSIA Psoriasis Treatment Market by Administration Route Type

    Oral

    Topical

    Injectable

    Intravenous

    RUSSIA Psoriasis Treatment Market by Indication Type

    Plaque Psoriasis

    Guttate Psoriasis

    Inverse Psoriasis

    Pustular Psoriasis

    RUSSIA Psoriasis Treatment Market by End User Type

    Hospital

    Dermatology Clinics

    Homecare Settings

    ITALY Outlook (USD Billion, 2019-2035)

    ITALY Psoriasis Treatment Market by Treatment Type

    Topical Treatments

    Systemic Treatments

    Phototherapy

    Biologics

    ITALY Psoriasis Treatment Market by Administration Route Type

    Oral

    Topical

    Injectable

    Intravenous

    ITALY Psoriasis Treatment Market by Indication Type

    Plaque Psoriasis

    Guttate Psoriasis

    Inverse Psoriasis

    Pustular Psoriasis

    ITALY Psoriasis Treatment Market by End User Type

    Hospital

    Dermatology Clinics

    Homecare Settings

    SPAIN Outlook (USD Billion, 2019-2035)

    SPAIN Psoriasis Treatment Market by Treatment Type

    Topical Treatments

    Systemic Treatments

    Phototherapy

    Biologics

    SPAIN Psoriasis Treatment Market by Administration Route Type

    Oral

    Topical

    Injectable

    Intravenous

    SPAIN Psoriasis Treatment Market by Indication Type

    Plaque Psoriasis

    Guttate Psoriasis

    Inverse Psoriasis

    Pustular Psoriasis

    SPAIN Psoriasis Treatment Market by End User Type

    Hospital

    Dermatology Clinics

    Homecare Settings

    REST OF EUROPE Outlook (USD Billion, 2019-2035)

    REST OF EUROPE Psoriasis Treatment Market by Treatment Type

    Topical Treatments

    Systemic Treatments

    Phototherapy

    Biologics

    REST OF EUROPE Psoriasis Treatment Market by Administration Route Type

    Oral

    Topical

    Injectable

    Intravenous

    REST OF EUROPE Psoriasis Treatment Market by Indication Type

    Plaque Psoriasis

    Guttate Psoriasis

    Inverse Psoriasis

    Pustular Psoriasis

    REST OF EUROPE Psoriasis Treatment Market by End User Type

    Hospital

    Dermatology Clinics

    Homecare Settings

    APAC Outlook (USD Billion, 2019-2035)

    APAC Psoriasis Treatment Market by Treatment Type

    Topical Treatments

    Systemic Treatments

    Phototherapy

    Biologics

    APAC Psoriasis Treatment Market by Administration Route Type

    Oral

    Topical

    Injectable

    Intravenous

    APAC Psoriasis Treatment Market by Indication Type

    Plaque Psoriasis

    Guttate Psoriasis

    Inverse Psoriasis

    Pustular Psoriasis

    APAC Psoriasis Treatment Market by End User Type

    Hospital

    Dermatology Clinics

    Homecare Settings

    APAC Psoriasis Treatment Market by Regional Type

    China

    India

    Japan

    South Korea

    Malaysia

    Thailand

    Indonesia

    Rest of APAC

    CHINA Outlook (USD Billion, 2019-2035)

    CHINA Psoriasis Treatment Market by Treatment Type

    Topical Treatments

    Systemic Treatments

    Phototherapy

    Biologics

    CHINA Psoriasis Treatment Market by Administration Route Type

    Oral

    Topical

    Injectable

    Intravenous

    CHINA Psoriasis Treatment Market by Indication Type

    Plaque Psoriasis

    Guttate Psoriasis

    Inverse Psoriasis

    Pustular Psoriasis

    CHINA Psoriasis Treatment Market by End User Type

    Hospital

    Dermatology Clinics

    Homecare Settings

    INDIA Outlook (USD Billion, 2019-2035)

    INDIA Psoriasis Treatment Market by Treatment Type

    Topical Treatments

    Systemic Treatments

    Phototherapy

    Biologics

    INDIA Psoriasis Treatment Market by Administration Route Type

    Oral

    Topical

    Injectable

    Intravenous

    INDIA Psoriasis Treatment Market by Indication Type

    Plaque Psoriasis

    Guttate Psoriasis

    Inverse Psoriasis

    Pustular Psoriasis

    INDIA Psoriasis Treatment Market by End User Type

    Hospital

    Dermatology Clinics

    Homecare Settings

    JAPAN Outlook (USD Billion, 2019-2035)

    JAPAN Psoriasis Treatment Market by Treatment Type

    Topical Treatments

    Systemic Treatments

    Phototherapy

    Biologics

    JAPAN Psoriasis Treatment Market by Administration Route Type

    Oral

    Topical

    Injectable

    Intravenous

    JAPAN Psoriasis Treatment Market by Indication Type

    Plaque Psoriasis

    Guttate Psoriasis

    Inverse Psoriasis

    Pustular Psoriasis

    JAPAN Psoriasis Treatment Market by End User Type

    Hospital

    Dermatology Clinics

    Homecare Settings

    SOUTH KOREA Outlook (USD Billion, 2019-2035)

    SOUTH KOREA Psoriasis Treatment Market by Treatment Type

    Topical Treatments

    Systemic Treatments

    Phototherapy

    Biologics

    SOUTH KOREA Psoriasis Treatment Market by Administration Route Type

    Oral

    Topical

    Injectable

    Intravenous

    SOUTH KOREA Psoriasis Treatment Market by Indication Type

    Plaque Psoriasis

    Guttate Psoriasis

    Inverse Psoriasis

    Pustular Psoriasis

    SOUTH KOREA Psoriasis Treatment Market by End User Type

    Hospital

    Dermatology Clinics

    Homecare Settings

    MALAYSIA Outlook (USD Billion, 2019-2035)

    MALAYSIA Psoriasis Treatment Market by Treatment Type

    Topical Treatments

    Systemic Treatments

    Phototherapy

    Biologics

    MALAYSIA Psoriasis Treatment Market by Administration Route Type

    Oral

    Topical

    Injectable

    Intravenous

    MALAYSIA Psoriasis Treatment Market by Indication Type

    Plaque Psoriasis

    Guttate Psoriasis

    Inverse Psoriasis

    Pustular Psoriasis

    MALAYSIA Psoriasis Treatment Market by End User Type

    Hospital

    Dermatology Clinics

    Homecare Settings

    THAILAND Outlook (USD Billion, 2019-2035)

    THAILAND Psoriasis Treatment Market by Treatment Type

    Topical Treatments

    Systemic Treatments

    Phototherapy

    Biologics

    THAILAND Psoriasis Treatment Market by Administration Route Type

    Oral

    Topical

    Injectable

    Intravenous

    THAILAND Psoriasis Treatment Market by Indication Type

    Plaque Psoriasis

    Guttate Psoriasis

    Inverse Psoriasis

    Pustular Psoriasis

    THAILAND Psoriasis Treatment Market by End User Type

    Hospital

    Dermatology Clinics

    Homecare Settings

    INDONESIA Outlook (USD Billion, 2019-2035)

    INDONESIA Psoriasis Treatment Market by Treatment Type

    Topical Treatments

    Systemic Treatments

    Phototherapy

    Biologics

    INDONESIA Psoriasis Treatment Market by Administration Route Type

    Oral

    Topical

    Injectable

    Intravenous

    INDONESIA Psoriasis Treatment Market by Indication Type

    Plaque Psoriasis

    Guttate Psoriasis

    Inverse Psoriasis

    Pustular Psoriasis

    INDONESIA Psoriasis Treatment Market by End User Type

    Hospital

    Dermatology Clinics

    Homecare Settings

    REST OF APAC Outlook (USD Billion, 2019-2035)

    REST OF APAC Psoriasis Treatment Market by Treatment Type

    Topical Treatments

    Systemic Treatments

    Phototherapy

    Biologics

    REST OF APAC Psoriasis Treatment Market by Administration Route Type

    Oral

    Topical

    Injectable

    Intravenous

    REST OF APAC Psoriasis Treatment Market by Indication Type

    Plaque Psoriasis

    Guttate Psoriasis

    Inverse Psoriasis

    Pustular Psoriasis

    REST OF APAC Psoriasis Treatment Market by End User Type

    Hospital

    Dermatology Clinics

    Homecare Settings

    South America Outlook (USD Billion, 2019-2035)

    South America Psoriasis Treatment Market by Treatment Type

    Topical Treatments

    Systemic Treatments

    Phototherapy

    Biologics

    South America Psoriasis Treatment Market by Administration Route Type

    Oral

    Topical

    Injectable

    Intravenous

    South America Psoriasis Treatment Market by Indication Type

    Plaque Psoriasis

    Guttate Psoriasis

    Inverse Psoriasis

    Pustular Psoriasis

    South America Psoriasis Treatment Market by End User Type

    Hospital

    Dermatology Clinics

    Homecare Settings

    South America Psoriasis Treatment Market by Regional Type

    Brazil

    Mexico

    Argentina

    Rest of South America

    BRAZIL Outlook (USD Billion, 2019-2035)

    BRAZIL Psoriasis Treatment Market by Treatment Type

    Topical Treatments

    Systemic Treatments

    Phototherapy

    Biologics

    BRAZIL Psoriasis Treatment Market by Administration Route Type

    Oral

    Topical

    Injectable

    Intravenous

    BRAZIL Psoriasis Treatment Market by Indication Type

    Plaque Psoriasis

    Guttate Psoriasis

    Inverse Psoriasis

    Pustular Psoriasis

    BRAZIL Psoriasis Treatment Market by End User Type

    Hospital

    Dermatology Clinics

    Homecare Settings

    MEXICO Outlook (USD Billion, 2019-2035)

    MEXICO Psoriasis Treatment Market by Treatment Type

    Topical Treatments

    Systemic Treatments

    Phototherapy

    Biologics

    MEXICO Psoriasis Treatment Market by Administration Route Type

    Oral

    Topical

    Injectable

    Intravenous

    MEXICO Psoriasis Treatment Market by Indication Type

    Plaque Psoriasis

    Guttate Psoriasis

    Inverse Psoriasis

    Pustular Psoriasis

    MEXICO Psoriasis Treatment Market by End User Type

    Hospital

    Dermatology Clinics

    Homecare Settings

    ARGENTINA Outlook (USD Billion, 2019-2035)

    ARGENTINA Psoriasis Treatment Market by Treatment Type

    Topical Treatments

    Systemic Treatments

    Phototherapy

    Biologics

    ARGENTINA Psoriasis Treatment Market by Administration Route Type

    Oral

    Topical

    Injectable

    Intravenous

    ARGENTINA Psoriasis Treatment Market by Indication Type

    Plaque Psoriasis

    Guttate Psoriasis

    Inverse Psoriasis

    Pustular Psoriasis

    ARGENTINA Psoriasis Treatment Market by End User Type

    Hospital

    Dermatology Clinics

    Homecare Settings

    REST OF SOUTH AMERICA Outlook (USD Billion, 2019-2035)

    REST OF SOUTH AMERICA Psoriasis Treatment Market by Treatment Type

    Topical Treatments

    Systemic Treatments

    Phototherapy

    Biologics

    REST OF SOUTH AMERICA Psoriasis Treatment Market by Administration Route Type

    Oral

    Topical

    Injectable

    Intravenous

    REST OF SOUTH AMERICA Psoriasis Treatment Market by Indication Type

    Plaque Psoriasis

    Guttate Psoriasis

    Inverse Psoriasis

    Pustular Psoriasis

    REST OF SOUTH AMERICA Psoriasis Treatment Market by End User Type

    Hospital

    Dermatology Clinics

    Homecare Settings

    MEA Outlook (USD Billion, 2019-2035)

    MEA Psoriasis Treatment Market by Treatment Type

    Topical Treatments

    Systemic Treatments

    Phototherapy

    Biologics

    MEA Psoriasis Treatment Market by Administration Route Type

    Oral

    Topical

    Injectable

    Intravenous

    MEA Psoriasis Treatment Market by Indication Type

    Plaque Psoriasis

    Guttate Psoriasis

    Inverse Psoriasis

    Pustular Psoriasis

    MEA Psoriasis Treatment Market by End User Type

    Hospital

    Dermatology Clinics

    Homecare Settings

    MEA Psoriasis Treatment Market by Regional Type

    GCC Countries

    South Africa

    Rest of MEA

    GCC COUNTRIES Outlook (USD Billion, 2019-2035)

    GCC COUNTRIES Psoriasis Treatment Market by Treatment Type

    Topical Treatments

    Systemic Treatments

    Phototherapy

    Biologics

    GCC COUNTRIES Psoriasis Treatment Market by Administration Route Type

    Oral

    Topical

    Injectable

    Intravenous

    GCC COUNTRIES Psoriasis Treatment Market by Indication Type

    Plaque Psoriasis

    Guttate Psoriasis

    Inverse Psoriasis

    Pustular Psoriasis

    GCC COUNTRIES Psoriasis Treatment Market by End User Type

    Hospital

    Dermatology Clinics

    Homecare Settings

    SOUTH AFRICA Outlook (USD Billion, 2019-2035)

    SOUTH AFRICA Psoriasis Treatment Market by Treatment Type

    Topical Treatments

    Systemic Treatments

    Phototherapy

    Biologics

    SOUTH AFRICA Psoriasis Treatment Market by Administration Route Type

    Oral

    Topical

    Injectable

    Intravenous

    SOUTH AFRICA Psoriasis Treatment Market by Indication Type

    Plaque Psoriasis

    Guttate Psoriasis

    Inverse Psoriasis

    Pustular Psoriasis

    SOUTH AFRICA Psoriasis Treatment Market by End User Type

    Hospital

    Dermatology Clinics

    Homecare Settings

    REST OF MEA Outlook (USD Billion, 2019-2035)

    REST OF MEA Psoriasis Treatment Market by Treatment Type

    Topical Treatments

    Systemic Treatments

    Phototherapy

    Biologics

    REST OF MEA Psoriasis Treatment Market by Administration Route Type

    Oral

    Topical

    Injectable

    Intravenous

    REST OF MEA Psoriasis Treatment Market by Indication Type

    Plaque Psoriasis

    Guttate Psoriasis

    Inverse Psoriasis

    Pustular Psoriasis

    REST OF MEA Psoriasis Treatment Market by End User Type

    Hospital

    Dermatology Clinics

    Homecare Settings

    Infographic

    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Get Free Sample

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne

    Founder
    Case Study
    Chemicals and Materials

    Compare Licence

    ×
    Features License Type
    Single User Multiuser License Enterprise User
    Price $4,950 $5,950 $7,250
    Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
    Free Customization
    Direct Access to Analyst
    Deliverable Format
    Platform Access
    Discount on Next Purchase 10% 15% 15%
    Printable Versions